Abstract
dc:descriptionGENETIC ALTERATIONS ARE FREQUENTLY ASSOCIATED WITH NEOPLASIA. THESE GENETIC CHANGES ALTER CELLULAR PROTO-ONCOGENES AND/OR THEIR "SUPPRESSOR" GENES AND CONTRIBUTE TO THE MANIFESTATIONS OF THE MALIGNANT PHENOTYPE. DESPITE BEING A COMMONCANCER IN THE WESTERN WORLD, RELATIVELY LITTLE IS KNOWN ABOUT THE MOLECULAR BASIS OF PANCREATIC CANCER. RECENT STUDIES HAVE SHOWN THAT THERE ARE ABNORMALITIES IN THE STRUCTURE AND/OR FUNCTION OF SOME ONCOGENES IN HUMAN PANCREATIC CANCER. IN THE PRESENT STUDY, EXPRESSION OF C-ERBB-2 AND RAS ONCOGENES WAS FOUNDIN 20% AND 75% OF CASES RESPECTIVELY. THIS EXPRESSION WAS PRESENT IN THE PRIMARY TUMOUR AND IN LIVER AND LYMPH NODES METASTASES. THESE GENETIC ALTERATIONSMIGHT FIND CLINICAL APPLICATIONS (BOTH DIAGNOSTIC AND THERAPEUTIC). THE WEAK EXPRESSION OF MYC AND FOS ONCOGENES WAS OBSERVED IN 10% OF CASES. THE EXPRESSION OF ONCOGENES IN HUMAN PANCREATIC CANCER IS NOT OF PROGNOSTIC SIGNIFICANCE.THE MAIN PROGNOSTIC FACTOR IS THE STAGE OF THE TUMOUR.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 1995
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Σακοράφας, Γεώργιος
Subjects
dc:subject × 16Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/5068